Current Status
Not Enrolled
Get Started

After the completion of this activity, the participant should be able to:

  1. Examine safety, efficacy, dosing, and administration of different therapies used for chronic inflammatory demyelinating polyneuropathy (CIDP)
  2. Analyze best practices for the transition from intravenous to subcutaneous immunoglobulin (IVIg to SCIG) among patients with CIDP
  3. Identify the role of clinical team members in monitoring therapy and optimizing the management of patients with CIDP

Leslie Myers, PharmD, IgCP®

Nursing 1 contact hour
ACPE 1 contact hour

1 IgCN® / IgCP® Recertification Units